Consorci Sanitari Del Maresme

Running trials

• Not yet recruiting

  Immunosuppressant Discontinuation in Elderly Patients With Ulcerative Colitis And Long-term Remission

  NCT07248644· Phase 4· Source

• Recruiting

  Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis (SchizOMICS)

  NCT06060886· Phase 4· Source

• Active, not recruiting

  A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

  NCT06311721· Phase 3· Source

• Active, not recruiting

  A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

  2023-508359-38-00· Phase 3· Source

• Active, not recruiting

  Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

  NCT05874401· Phase 4· Source

• Active, not recruiting

  DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors

  NCT05684276· Phase 2· Source

• Active, not recruiting

  Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

  NCT04595565· Phase 3· Source

• Active, not recruiting

  Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combination with biologic drugs (panitumumab and bevacizumab).

  NCT03635021· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting
• Schizophrenia1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer. “ALPHABET Study”

  NCT05063786· Phase 3· Source

• Completed

  Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

  NCT04736173· Phase 2· Source